Explore

FDA Draft Guidance Refines Approval Process for Individualized Genetic Therapies

FDA Draft Guidance Refines Approval Process for Individualized Genetic Therapies

The U.S. Food and Drug Administration (FDA) has released draft guidance titled 'Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause.' This guidance aims to adapt the regulatory approval process for individualized genetic interventions, particularly for rare genetic disorders affecting a small number of patients. Traditionally, each variant-specific modification would require its own investigational new drug application (IND) and extensive testing, which is economically and logistically infeasible for 'n-of-1' or 'n-of-few' patient populations. The new framework outlines five key elements for approval: a specific genetic abnormality with a clear link to disease, a therapy targeting the underlying pathology, a well-characterized natural history of the disease, confirmation of successful targeting, and demonstrated improvement in clinical outcomes. The draft guidance provides more detail on nonc...

Gamgee Launches Personalized mRNA Cancer Vaccines for Dogs, Aims for Cross-Species Application

Gamgee Launches Personalized mRNA Cancer Vaccines for Dogs, Aims for Cross-Species Application

Gamgee, a new biotechnology company, has launched with $4 million in seed funding to develop personalized mRNA cancer vaccines for dogs. The company's approach involves sequencing each dog's tumor to identify unique, tumor-specific neoantigens. These neoantigens are then encoded into an mRNA vaccine, designed to train the dog's immune system to recognize and attack its specific cancer. This initiative was inspired by the founder, Paul Conyngham, who developed a personalized treatment for his own rescue dog, Rosie, after traditional therapies failed. Rosie's treatment, which involved genomics, AI, and mRNA technology, laid the groundwork for Gamgee's platform. Clinical studies for these personalized vaccines are currently underway in Australia, with the company working to establish the appropriate regulatory pathways for patient-specific veterinary biologics in the U.S. Gamgee's long-term vision extends beyond veterinary medicine, aiming to make personalized mRNA vaccines accessible through veterinary oncol...

VA Initiates Psilocybin Clinical Trial for Veterans with Treatment-Resistant Depression and PTSD

VA Initiates Psilocybin Clinical Trial for Veterans with Treatment-Resistant Depression and PTSD

The Department of Veterans Affairs (VA) has launched a multi-site clinical trial, named 'Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression' (PIVOT), to assess the safety and effectiveness of psilocybin for veterans suffering from treatment-resistant major depressive disorder, including those with co-occurring post-traumatic stress disorder (PTSD). This randomized, double-blind controlled study will compare outcomes across various dosage levels. Participants will undergo structured psychological preparation, guided administration sessions in controlled healthcare environments, and post-session integration therapy led by trained clinical facilitators. Researchers will monitor patient-reported depression scores, adverse effect tolerability, and changes in overall mental health over several months. The trial is being conducted at five VA medical facilities: Birmingham VA Health Care System (Alabama), Tuscaloosa VA Medical Center (Alabama), VA Portland Health Care System (Oregon), C...

Trump praises Joe Rogan-backed ibogaine. What is it?

Trump praises Joe Rogan-backed ibogaine. What is it?

President Donald Trump is giving renewed attention to the psychedelic drug ibogaine. Here's what to know about it.

AstraZeneca and HUTCHMED Announce Positive Phase III Results for TAGRISSO Plus Savolitinib in Lung Cancer

AstraZeneca and HUTCHMED Announce Positive Phase III Results for TAGRISSO Plus Savolitinib in Lung Cancer

AstraZeneca and HUTCHMED have reported positive high-level results from the SAFFRON Phase III trial, demonstrating that TAGRISSO (osimertinib) combined with savolitinib significantly improved progression-free survival (PFS) and overall survival (OS) in patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This trial focused on patients whose tumors exhibited high levels of MET overexpression or amplification and had progressed after prior treatment with TAGRISSO. MET-driven resistance is a common mechanism of progression in EGFRm NSCLC patients treated with third-generation EGFR-tyrosine kinase inhibitors (TKIs), often leading to poor prognosis and a lack of effective, well-tolerated treatment options. The safety profile of the combination therapy was consistent with the known profiles of each medicine, with no new safety findings observed. These findings reinforce TAGRISSO as a foundational therapy in EGFRm lung cancer and highlight the potential of this novel ...

Nurtured Nuts Co. Develops Hypoallergenic Peanut Using CRISPR Technology for Restricted Markets

Nurtured Nuts Co. Develops Hypoallergenic Peanut Using CRISPR Technology for Restricted Markets

Nurtured Nuts Co. Develops Hypoallergenic Peanut Using CRISPR Technology for Restricted Markets

Congressional Delay of Food Traceability Rule Sparks Debate Among Lawmakers and Industry

Congressional Delay of Food Traceability Rule Sparks Debate Among Lawmakers and Industry

A provision, Section 780, in the fiscal 2026 continuing appropriations bill, H.R. 5371, has barred the Food and Drug Administration (FDA) from using funds to administer or enforce the Food Traceability Rule before July 20, 2028. This delay was a result of lobbying efforts by several industry associations, including the International Foodservice Distributors Association and the National Restaurant Association, which explicitly supported a 30-month compliance date extension and targeted flexibilities. The original bill to relax the traceability rule, H.R. 7563, was introduced by Representative Scott Franklin of Florida and co-sponsored by Representative Sanford Bishop of Georgia and Representative Jimmy Panetta of California. Both Franklin and Bishop sit on the House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration and Related Agencies, which has jurisdiction over the FDA's funding. The Senate, in contrast, had initially directed that the FDA should not delay enforc...

L-Nutra Issues Allergy Alert for Undeclared Tree Nuts in Prolon Brand Apulian Almond Cocoa Spread

L-Nutra, a company based in Culver City, California, has issued an allergy alert and is recalling its Prolon brand Apulian Almond & Cocoa Spread due to the presence of undeclared cashew, pistachio, and hazelnut. The product, packaged in 8.47oz (240g) glass jars with UPC 850040360530, specifically lot L2755 with an expiration date of January 2, 2027, was distributed through L-Nutra's e-commerce site, ProlonLife.com, both as direct purchases and as part of product bundles. The recall was initiated after testing confirmed the presence of these tree nut allergens, which were not disclosed on the product's label. To date, one confirmed allergic reaction associated with this product has been documented. The cause of the undeclared allergens is currently under investigation, and at this time, only Lot L2755 is known to be affected.

FDA Selects Cadence's HypertensionOS for TEMPO Pilot Program to Evaluate Digital Health Technology

FDA Selects Cadence's HypertensionOS for TEMPO Pilot Program to Evaluate Digital Health Technology

The U.S. Food and Drug Administration (FDA) has chosen Cadence's HypertensionOS as the second participant in its Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program. HypertensionOS is a software as a medical device (SaMD) designed to assist clinicians in managing medication for patients diagnosed with stage 2 hypertension. This selection is part of a broader FDA initiative, in collaboration with the Centers for Medicare & Medicaid Services (CMS) Innovation Center’s Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model. The TEMPO pilot aims to facilitate access to specific digital health technologies while ensuring patient safety and gathering real-world evidence on their clinical application. HypertensionOS incorporates AI-assisted features to support licensed healthcare professionals, such as physicians and Advanced Practice Registered Nurses, in medication initiation and titration workflows within predefined eligibility conditions and deterministic safety checks for ou...

Genomics Market Sees Sustained Growth Driven by Declining DNA Sequencing Costs and Technological Advancements

Genomics Market Sees Sustained Growth Driven by Declining DNA Sequencing Costs and Technological Advancements

The genomics market is experiencing continuous growth, primarily due to the decreasing cost of DNA sequencing and ongoing innovations in next-generation sequencing (NGS) technologies. This increased affordability has led to a broader adoption of various sequencing methods, including whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted sequencing, and transcriptome analysis. These technologies are being applied across diverse fields such as oncology, rare disease diagnosis, reproductive health, pharmacogenomics, and infectious disease surveillance. Government initiatives, like the National Institutes of Health (NIH) All of Us Research Program, and substantial funding for genomic research are further accelerating the integration of genomics into disease prevention, personalized medicine, and population health studies. The market expansion is also fueled by rising investments in precision medicine and personalized healthcare, alongside continuous reductions in sequencing costs and advancement...

Dermatologist Advises Caution on Topical Isotretinoin for Acne Treatment

Dermatologist Advises Caution on Topical Isotretinoin for Acne Treatment

Dr. John Barbieri, Director of the advanced acne therapeutics clinic at Brigham and Women’s Hospital, advises against the use of topical isotretinoin for acne treatment, particularly for teenagers. Despite its marketing as an alternative to oral isotretinoin, clinical trials indicate that topical isotretinoin does not outperform other established topical retinoids like adapalene or tretinoin. Furthermore, topical isotretinoin is not an FDA-licensed product in the United States and must be compounded. This compounding process introduces potential risks due to less regulated quality controls compared to products available through regular pharmacies. Dr. Barbieri emphasizes that there is no scenario where he would consider topical isotretinoin superior to other over-the-counter (OTC) options.

First Ascent Biomedical Appoints Dr. Gilberto Lopes as Chairman of Medical Advisory Board to Advance Functional Precision Oncology

First Ascent Biomedical Appoints Dr. Gilberto Lopes as Chairman of Medical Advisory Board to Advance Functional Precision Oncology

First Ascent Biomedical, a precision oncology company, has announced the appointment of Dr. Gilberto Lopes as the Chairman of its Medical Advisory Board. Dr. Lopes, who is the Chief of the Division of Medical Oncology at the University of Miami Miller School of Medicine and Associate Director for Global Oncology at Sylvester Comprehensive Cancer Center, will guide the company's scientific strategy, clinical study design, health-economic research, and the development of standards for Functional Precision Oncology (FPO). This appointment comes at a crucial time for FPO, especially following a recent Clinical Notice from the American Society of Clinical Oncology (ASCO) that distinguished contemporary Functional Precision Medicine from older chemosensitivity assays. ASCO's notice supports the advancement of modern FPM to improve clinical outcomes and clarifies that historical guidelines should not impede research or patient access to contemporary FPM assays. First Ascent Biomedical's xDRIVE platform combines l...